FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
|Articles|February 6, 2019
Meissner Announces New Manufacturing Facility
Author(s)BioPharm International Editors
The company will open its first European manufacturing facility in Castlebar, Ireland.
Advertisement
On Feb. 1, 2019, Meissner Filtration Products, a developer, manufacturer, and supplier of microfiltration and single-use systems, announced plans to establish a new manufacturing facility in County Mayo, Ireland.
Meissner will expand an existing 34,000-ft2 advanced technology building constructed by the Industrial Development Authority (IDA) Ireland in Castlebar to 100,000 ft2. The company has also purchased the adjacent land to more than triple the facility’s current footprint, and plans to install a large, state-of-the-art cleanroom within the existing facility to be used for the manufacture of single-use systems (SUS). The new facility is expected to be operational in the first quarter of 2020. Initial operations will include SUS manufacturing, quality and regulatory, engineering, and customer service.
“We have seen substantial growth in our SUS portfolio over the past 10 years, and ensuring we have capacity in excess of customer demand is critical,” stated Christopher Meissner, CEO of Meissner Filtration Products, in a company press release. “Additionally, we acutely recognize the value of manufacturing proximate to our customer base as well as geographically diversifying our manufacturing footprint.”
Currently, Meissner has a manufacturing campus in Camarillo, CA, and a European logistics hub outside of Frankfurt, Germany. The company reports that the Castlebar facility will be its first manufacturing facility in Europe, creating over 150 jobs over the next five years.
Source:
Advertisement
Related to this article
CordenPharma is expanding its Caponago, Italy site with a €80 million multi-year investment and new aseptic fill-finish lines, aiming to reach 500 million sterile injectable units of annual capacity to meet rising demand across peptide, biologic, LNP, and oligonucleotide-based drug products.
Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Advertisement
Advertisement